Zhang Ye,Zhang Yin,Jiang Jiabin,et al.Short-term efficacy and safety of low-dose solifenacin for newly diagnosed idiopathic overactive bladder in children[J].Journal of Clinical Pediatric Surgery,,22():134-138.[doi:10.3760/cma.j.cn101785-202210053-007]
Short-term efficacy and safety of low-dose solifenacin for newly diagnosed idiopathic overactive bladder in children
- Keywords:
- Overactive Bladder; Folifenacin; Drug Therapy; Treatment Outcome; Patient Safety; Child
- Abstract:
- Objective To explore the short-term efficacy and safety of solifenacin for newly diagnosed idiopathic overactive bladder(IOAB)in children.Methods Between January and August 2022,clinical data of 3-day voiding diaries and overactive bladder symptom score(OABSS)were reviewed for 27 IOAB outpatients.Behavior therapy and 2.5 mg fixed oral daily dose solifenacin succinate were offered for 4 weeks.The efficacy and safety were evaluated at 2/4 weeks after medication.Results After 2-week medication,mean total OABSS declined markedly as compared to baseline value [9(7,12)vs.7(4,8),Z=-4.506,P<0.001].Voiding urgency [4(3,5)vs.3(3,4),Z=-4.025,P<0.001] and urgency urinary incontinence(UUI)[4(1,4)vs.2(0,3),Z=-4.373,P<0.001] significantly improved after 2-week treatment.Mean frequency during daytime decreased from(14.7±3.8)to(9.5±2.5)times(t=12.013,P<0.001,95%CI4.33,6.12)and mean voided volume spiked from(51.78±21.98)to(96.85±29.91)ml(t=-9.591,P<0.001,95%CI-47.45,-30.69)as compared to baseline data.At the end,complete continence was achieved(n=13,48.1%)and OAB symptoms improved(n=13).One patient complained of nausea,abdominal distension and constipation.No significant adverse effects were noted.Conclusion Solifenacin succinate 2.5 mg fixed dose for 2 weeks may be used for pediatric OAB.It can significantly improve the symptoms of OAB with decent safety and compliance.
References:
[1] Akbal C, ?ahan A, ?ener TE,et al.Diagnostic value of the pediatric lower urinary tract symptom score in children with overactive bladder[J].World J Urol,2014,32(1):201-208.DOI:10.1007/s00345-013-1224-y.
[2] Franco I.Overactive bladder in children[J].Nat Rev Urol,2016,13(9):520-532.DOI:10.1038/nrurol.2016.152.
[3] 尚小平,杨静,汪玺正,等.儿童日间尿失禁流行病学调查及尿不湿的应用对其影响分析[J].中华医学杂志,2018,98(18):1434-1438.DOI:10.3760/cma.j.issn.0376-2491.2018.18.013. Shang XP,Yang J,Wang XZ,et al.Epidemiological survey and analysis of the effect of using diapers on daytime urinary incontinence in children[J].Natl Med J China,2018,98(18):1434-1438.DOI:10.3760/cma.j.issn.0376-2491.2018.18.013.
[4] 牛之彬,杨屹.生物反馈联合电刺激治疗儿童功能性排尿失调的初步研究[J].临床小儿外科杂志,2020,19(11):991-995.DOI:10.3969/j.issn.1671-6353.2020.11.006. Niu ZB,Yang Y.Biofeedback therapy plus electrical nerve stimulation for dysfunctional voiding in children[J].J Clin Ped Sur,2020,19(11):991-995.DOI:10.3969/j.issn.1671-6353.2020.11.006.
[5] Soliman MG,El-Abd S,El-Gamal OM,et al.Mirabegron versus solifenacin in children with overactive bladder:prospective randomized single-blind controlled trial[J].Urol Int,2021,105(11/12):1011-1017.DOI:10.1159/000515992.
[6] 郭立华,张谦,范应中,等.索利那新治疗小儿尿道下裂术后膀胱痉挛的疗效分析[J].中华泌尿外科杂志,2016,37(6):454-457.DOI:10.3760/cma.j.issn.1000-6702.2016.06.015. Guo LH,Zhang Q,Fan YZ,et al.Efficacy of solifenacin for bladder spasm after operations for pediatric hypospadias[J].Chin J Urol,2016,37(6):454-457.DOI:10.3760/cma.j.issn.1000-6702.2016.06.015.
[7] Peyronnet B,Mironska E,Chapple C,et al.A comprehensive review of overactive bladder pathophysiology:on the way to tailored treatment[J].Eur Urol,2019,75(6):988-1000.DOI:10.1016/j.eururo.2019.02.038.
[8] Ramsay S,Naud é,Simonyan D,et al.A randomized,crossover trial comparing the efficacy and safety of fesoterodine and extended-release oxybutynin in children with overactive bladder with 12-month extension on fesoterodine:the FOXY study[J].Can Urol Assoc J,2020,14(6):192-198.DOI:10.5489/cuaj.6247.
[9] Brucker BM,Lee RK,Newman DK.Optimizing nonsurgical treatments of overactive bladder in the United States[J].Urology,2020,145:52-59.DOI:10.1016/j.urology.2020.06.017.
[10] M受体拮抗剂临床应用专家共识编写组.M受体拮抗剂临床应用专家共识[J].中华泌尿外科杂志,2014,35(2):81-86.DOI:10.3760/cma.j.issn.1000-6702.2014.02.001. Expert Consensus Compiling Group on Clinical Application of M-Receptor Antagonists.Expert Consensus on Clinical Application of M-Receptor Antagonists[J].Chin J Urol,2014,35(2):81-86.DOI:10.3760/cma.j.issn.1000-6702.2014.02.001.
[11] 中华医学会小儿外科学分会小儿尿动力和盆底学组,中华医学会小儿外科学分会泌尿外科学组.儿童膀胱过度活动症诊断和治疗中国专家共识[J].中华医学杂志,2021,101(40):3278-3286.DOI:10.3760/cma.j.cn112137-20210529-01232. Group of Pediatric Urodynamics and Pelvic Floor,Society of Pediatric Surgery,Chinese Medical Association;Urology Group,Society of Pediatric Surgery,Chinese Medical Association:Chinese Expert Consensus on Diagnosing and Treating Overactive Bladder in Children[J].Natl Med J China,2021,101(40):3278-3286.DOI:10.3760/cma.j.cn112137-20210529-01232.
[12] Hoebeke P,De Pooter J,De Caestecker K,et al.Solifenacin for therapy resistant overactive bladder[J].J Urol,2009,182(4 Suppl):2040-2044.DOI:10.1016/j.juro.2009.05.100.
[13] Tannenbaum S,den Adel M,Krauwinkel W,et al.Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity[J].Pharmacol Res Perspect,2020,8(6):e00684.DOI:10.1002/prp2.684.
[14] Newgreen D,Bosman B,Hollestein-Havelaar A,et al.Long-term safety and efficacy of solifenacin in children and adolescents with overactive bladder[J].J Urol,2017,198(4):928-936.DOI:10.1016/j.juro.2017.05.038.
[15] Ghanavati PM,Khazaeli D,Amjadzadeh M.A comparison of the efficacy and tolerability of treating primary nocturnal enuresis with solifenacin plus desmopressin,tolterodine plus desmopressin,and desmopressin alone:a randomized controlled clinical trial[J].Int Braz J Urol,2021,47(1):73-81.DOI:10.1590/S1677-5538.IBJU.2019.0448.
Memo
收稿日期:2022-10-25。
基金项目:安徽医科大学校科研基金项目(2020xkj252)
通讯作者:潮敏,Email:cm0654@sina.com